DALLAS, Texas — Biometric Signature ID (BSI) announces that it submitted formal comments to the U.S. Drug Enforcement Administration (DEA) in response to the agency’s request for comments on the Interim Final Rule enabling electronic prescribing (ePrescribing) of controlled substances. BSI introduced its BioSig-ID(TM) software biometric as a logical solution for the DEA’s identity authentication […]
